CEO Torsten Freltoft summarizes 2022
For AcouSort, 2022 was in many ways a good year. As the pandemic restrictions were lifted, we were able to intensify our important marketing work while strengthening our commercial organization through several significant recruitments. On the innovation side, the large grant we received from the European Innovation Council (EIC) to develop groundbreaking technology for exosome-based diagnostics was especially notable. Before we now go full force into 2023, we would like to give an overview of what AcouSort achieved in 2022.
Read CEO Torsten Freltoft’s summary of the past year in this Börsvärlden article: (Swedish) https://borsvarlden.com/artiklar/AcouSort-gar-in-i-2023-med-starkt-kommersiell-formaga.